Ulcerative Colitis Narrative Global Survey Findings: The Impact of Living With Ulcerative Colitis-Patients

Inflamm Bowel Dis. 2021 Feb 2;izab016. doi: 10.1093/ibd/izab016. Online ahead of print.

Marla C Dubinsky 1, Kenji Watanabe 2, Pauliina Molander 3, Laurent Peyrin-Biroulet 4, Michele Rubin 5, Gil Y Melmed 6, J Jasper Deuring 7, John Woolcott 8, Joseph C Cappelleri 9, Kathy Steinberg 10, Susan Connor 11


Author information

  • 1Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • 2Hyogo College of Medicine, Hyogo, Japan.
  • 3Abdominal Center, Gastroenterology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
  • 4Nancy University Hospital, Lorraine University, Vandœuvre-lès-Nancy, France.
  • 5University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, Illinois, USA.
  • 6Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • 7Pfizer Inc, Rotterdam, The Netherlands.
  • 8Pfizer Inc, Collegeville, Pennsylvania, USA.
  • 9Pfizer Inc, Groton, Connecticut, USA.
  • 10The Harris Poll, New York, New York, USA.
  • 11Liverpool Hospital, South Western Sydney Clinical School, University of New South Wales, Ingham Institute of Applied Medical Research, Liverpool, New South Wales, Australia.


Background: The Ulcerative Colitis (UC) Narrative is a global patient and physician survey aimed at identifying the impact of UC and comparing and contrasting perceptions of UC burden and management approaches.

Methods: Surveys of patients with UC (self-reported diagnosis; n = 2100) and physicians (n = 1254) were completed across 10 countries by The Harris Poll between August 2017 and February 2018. Questionnaires covered multiple aspects of UC, including diagnosis, treatment, and impact on patient quality of life, in addition to standard demographic information. Descriptive statistics are reported.

Results: The majority of patients (82%) had moderate to severe UC (based on medication history; those who had only ever taken 5-aminosalicylates were excluded); 67% described their UC as controlled with few to no symptoms. On average, patients experienced 4.3 flares (standard deviation, 7.4) in the past year. Diagnostic delay was on average 2.0 years (standard deviation, 5.4); 42% of patients waited ≥1 year. Most patients (65%) felt that UC controlled their life rather than them controlling their disease. Because of the fear of repercussions, many patients had not disclosed their UC to their employer. Discussion of the emotional impact of UC during routine appointments was less of a priority for physicians, compared with patients.

Conclusions: The data from this global survey highlight that patients with UC experience diagnostic delay, poor disease control, and adverse impact on their quality of life. Patients report UC to be a mentally exhausting condition; however, emotional and mental health issues are infrequently discussed at routine appointments.

© Copyright 2013-2024 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.